Search for content, post, videos

Implantica’s offering attracted strong interest

Peter Forsell

Implantica, a medtech group with operations within the implantable medical device and eHealth markets, announces the outcome of the offering in connection with the company’s listing on Nasdaq First North Premier Growth Market.

The offering, including the Overallotment Option, consists of 19,461,537 Swedish Depository Receipts (“SDRs”), representing newly issued class A shares in Implantica (the “Offering”). The Offering attracted very strong interest from both Swedish and international institutions as well as the general public in Sweden and was substantially oversubscribed.

New investors

New investors include several well-respected Swedish and international institutions, as well as the five cornerstone investors: Swedbank Robur Ny Teknik, Handelsbanken Fonder on behalf of managed funds, TIN Fonder, Skandia and Nordea Asset Management on behalf of, amongst others, the fund Nordea Innovation Stars, states the company in its press release.

Immediately following the completion of the Offering, and provided that the Overallotment Option is exercised in full, Implantica’s three largest shareholders will consist of Implantica MediSwiss AG (69.8 percent of the share capital and 82.2 percent of the votes), Swedbank Robur Ny Teknik (6.0 percent of the share capital and 3.5 percent of the votes) and Handelsbanken Fonder AB on behalf of investment Funds (4.8 percent of the share capital and 2.8 percent of the votes).

Trading commence today

Trading of the SDRs in Implantica on Nasdaq First North Premier Growth Market will commence today, 21 September 2020, under the ticker “IMP A SDB” (ISIN: SE0014855029). Trading is conditional until the settlement day of the Offering, which is expected to be 23 September 2020.

“The interest in Implantica has been overwhelming and the Offering was heavily oversubscribed. I would like to personally thank all the investors as well as Pareto Securities and Nasdaq who have supported us throughout this exciting journey. As you all know, we target a paradigm shift in acid reflux treatment and are now provided the opportunity to bring eHealth and advanced technology into the body based on our two platform technologies,” says Dr. Peter Forsell, CEO and founder of Implantica.

Photo of Peter Forsell: Implantica